Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
New Measure Might Better Define Efficacy Post-Transplant
Biol Blood Marrow Transplant; ePub 2017 Apr 5; Solomon, et al
A new measure using current graft-versus-host disease (GVHD)-free relapse-free survival (CGRFS) may predict long-term allogeneic transplant effectiveness better than the conventional approach, according to a study involving 422 individuals.
Participants received an allogeneic transplant at a single center between 2010 and 2015. Among the results:
- 3-year overall survival was 60%; disease-free survival was 54%.
- Over years 1-4 post-transplant, rates of conventionally defined GVHD-free, relapse-free survival were 33%, 26%, 23%, and 22%.
- Rates as defined by CGRFS were 45%, 46%, 47%, and 49%.
- Moderate-severe chronic GVHD rates decreased as follows over 4 years: 23%, 14%, 7% and 4%.
The authors noted that whereas ~one-fourth of patients achieved transplant success when defined conventionally, nearly half of patients defined by the new measure were considered cured without ongoing GVHD morbidity.
Solomon S, Sizemore C, Zhang X, et al. Current GVHD-free, relapse-free survival – A dynamic endpoint to better define efficacy following allogenic transplant. [Published online ahead of print April 5, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.02.022.